Navigation Links
OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering

OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Stock Offering Click to view news release full screen  

OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering


BOTHELL, WA, and VANCOUVER, Oct. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has completed a public offering of 3,174,602 units at a price to the public of $15.75 per unit for an aggregate offering amount of $50 million, as previously announced on October 18, 2010. The net proceeds to OncoGenex, after underwriting discounts and commissions and other offering expenses, from the sale of the units is approximately $46.7 million. The Company intends to use the net proceeds from the offering primarily to advance its product pipeline, including its lead program, custirsen, and OGX-427, which is currently in clinical development as a treatment for prostate cancer and bladder cancer, as well as for general corporate purposes. 

Stifel Nicolaus Weisel acted as sole book-running manager and Needham & Company, LLC, Rodman & Renshaw, LLC and Wedbush PacGrow Life Sciences acted as co-managers.

The offering was made to purchasers outside of Canada pursuant to an effective shelf registration statement that OncoGenex filed with the Securities and Exchange Commission, or the SEC, on June 26, 2009, as amended on July 13, 2009.  A final prospectus supplement relating to the offering was filed with the SEC on October 19, 2010. Copies of the prospectus supplement and the prospectus relating to these securities may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attention: General Counsel, (415) 364-2500.  Electronic copies of the prospectus supplement and accompanying prospectus are also available on the website of the SEC at

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock and warrants of OncoGenex Pharmaceuticals, Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.  OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.  More information about OncoGenex is available at

More information about OncoGenex is available at OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, OncoGenex' estimate of the net proceeds of the public offering and the anticipated use of such proceeds.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, the economic and/or market conditions generally, risks relating to OncoGenex' operations and financial performance and the factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for second fiscal quarter of 2010 and the preliminary prospectus supplement to be filed with the SEC.  The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
3. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
6. OncoGenex Reports Second Quarter Financial Results
7. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. OncoGenex Reports First Quarter Financial Results
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
(Date:10/8/2015)... PORTLAND, Oregon , October 8, 2015 /PRNewswire/ ... . --> Global Biologics and Biosimilars ... added a report "Global Biologics and Biosimilars Industry ... Growth, Analysis and Forecast" is a professional and ... Biosimilars industry . ) , ...
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, ... agreement to develop and commercialize intellectual property rights belonging to The University of ... 2009, and affords exclusive worldwide rights to intellectual property based on use of ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
Breaking Biology Technology:
... Green Mountain Energy Company to take the necessary steps in ... enabling them to operate as a "carbon neutral" analytical laboratory. ... ... Alkemists Pharmaceuticals today announced that it has partnered with Green Mountain ...
... 30 , - Shares Acquired From Biggar ... biotechnology company,focused on eye disease, vascular disease and ... based in Belgium have together acquired an 8%,stake ... Biggar Limited, a,charitable foundation that is ThromboGenics largest ...
... SAN DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... second quarter 2008,financial results after the NASDAQ Global ... afternoon, Jack Lief, Arena,s President and Chief,Executive Officer, ... Chief Financial Officer, will host a conference call ...
Cached Biology Technology:
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):
... began a rapid period of change called the Cambrian ... life forms over many millions of years that ultimately ... help palaeontologists chronicle the evolution of life since then, ... billion years that preceded the Cambrian Period is challenging, ...
... turnover and remodelling of lipid membranes could help phytoplankton cope ... team led by Patrick Martin of the National Oceanography Centre ... rapidly change the chemical composition of its cell membranes in ... the process may be important for nutrient cycling and the ...
... University researchers focusing on rice genetics are providing a ... nutrients. Their research provides insight into ways of ... research. Frank White, professor of plant pathology, and ... in partnership with researchers at three other institutions, of ...
Cached Biology News:
MAb to Myoglobin Cardiac...
... ALH 4000 workstation is the simplest, easiest-to-use ... introduce automated liquid handling capabilities,into their labs, ... to support routine applications on a separate ... walk-away automation even when you have ...
... Covance has generated hybridomas against a ... project initiation, you are provided with ... Hybridoma cell lines developed by Covance ... A typical hybridoma development project has ...
... normalization is essential for hunting and ... approaches, such as EST sequencing projects, ... methods are not well suited for ... Evrogen TRIMMER kit, though, is specially ...
Biology Products: